Lahore: BF Biosciences Limited has released its financial report for the fiscal year ending June 30, 2026, revealing a substantial increase in revenue and profits. The detailed financial results, dated September 29, 2026, indicate a notable growth trajectory for the company in its designated market category.
The company reported a revenue of 9.46 billion rupees for the year, a substantial rise from the 5.84 billion rupees recorded in 2025. This represents a very large or significant move of 62.09%. The cost of goods sold also increased to 5.37 billion rupees from 3.55 billion rupees in the previous year. Consequently, BF Biosciences Limited's gross profit increased significantly to 4.09 billion rupees, compared to 2.29 billion rupees in 2025.
Profit after taxation stood at 632.13 million rupees, up from 447.15 million rupees in the prior year, marking a very large or significant move of 41.37%. The earnings per share rose to 7.16 rupees from 5.52 rupees.
According to information available from the Pakistan Stock Exchange (PSX), BF Biosciences Limited's financial stability is underscored by its equity and liabilities, which reached 9.18 billion rupees, a growth from 8.16 billion rupees in 2025. The company's total assets were reported at 9.18 billion rupees, compared to 8.16 billion rupees the previous year.
The report also highlighted a moderate increase in administrative expenses, which rose to 202.50 million rupees from 60.57 million rupees in 2025, and a significant increase in selling and distribution expenses, reaching 2.70 billion rupees compared to 1.45 billion rupees the year before.
BF Biosciences Limited's net cash used in operating activities was 26.51 million rupees, contrasting with a net cash generation of 299.79 million rupees in 2025. Cash flow from investing activities generated 273.25 million rupees, a reversal from the previous year's net usage of 1.34 billion rupees.
The company's financing activities resulted in a net cash usage of 319.84 million rupees, compared to a net cash generation of 1.17 billion rupees in the previous year. The year-end cash and cash equivalents were reported at 249.34 million rupees, a decrease from 322.44 million rupees in 2025.
BF Biosciences Limited's financial results reflect a strong operational performance and a strategically enhanced market position for the year 2026.